LUCIDITY Phase III data is imminent; Amylyx has already flipped from trial sponsor to launch operator — and the stock has run 136% in 90 days ahead of the readout.
AMLX · Earnings Call · 2026-08-06
The Catalyst Arrives
Amylyx has crossed the last operational line on its most important asset. The pivotal Phase III LUCIDITY trial is fully through its double-blind period — the last patient completed their final visit. As Co-CEO Justin Klee put it: “The last participant has recently completed their last visit in the trial. We are on track and eagerly anticipating the top-line data readout in late August or early September.” — Justin Klee, Co-CEO · 2026-08-06 The company remains blinded, the database is not yet locked, and they have entered a quiet period — the calm before what is effectively a binary event.
The stakes are stark. The condition is driven by an exaggerated GLP-1 response after gastric bypass, and avexitide is a first-in-class GLP-1 receptor antagonist built to blunt exactly that endocrine cascade. Five prior avexitide trials in post-bariatric hypoglycemia all showed statistically significant reductions in hypoglycemic events, earning FDA breakthrough therapy designation. The company has been telling a remarkably consistent story across quarters — repeatedly citing the strong prior data and conservative powering.
The recurring analyst anxiety has been the placebo response. Management has stressed that even a 50% placebo assumption leaves robust power, as Camille Bedrosian stated: “LUCIDITY is designed to replicate those Phase II studies and we have powered the study very conservatively even in the face of those very highly significant studies.” — Camille Bedrosian, Chief Medical Officer · 2026-08-06
We powered the study to be 90% powered to detect a 35% treatment effect with even an up to 50% placebo effect.
That conservatism is deliberate. A year ago the enrollment timeline had slipped —
That's why we're updating the projections to now estimated completion of recruitment in the first quarter.
Each quarter the placebo question returned, and each time management leaned on the same answer. In Q4 2025, “we really do not expect much of a placebo response.” — Joshua B. Cohen, Co-Chief Executive Officer · 2026-03-03
The Launch Machinery Is Already Running
What is genuinely new this quarter is not the trial — it is the commercial operation built around it. Management laid out a fully-formed launch narrative: the disease state education campaign "Uncover the Mystery of Post-Bariatric Hypoglycemia" is live with UncoverPBH.com; a field medical affairs team is deployed for HCP scientific exchange; and the Early Access Program is now open to LUCIDITY completers and prior-trial participants, with demand building.
Commercial chief Dan Monahan repeated the ~160,000 U.S. PBH population estimate, now "supported by our independent claims analysis, ongoing field insights, and a growing body of published prospective and retrospective literature." A notable structural tailwind arrived in late June: CMS and CDC published their 2027 ICD-10 code files including a code specific to PBH, effective October 1, 2026 — a recognition milestone the company says aids diagnosis tracking even though it is not required for reimbursement. This continues a long-running ICD-10 code theme across several calls.
Beyond the Binary: Platform and Pipeline
Avexitide is the headline, but Amylyx is quietly broadening its scientific footing. A second research collaboration with Gubra — following the one that produced AMX0318 — will "screen and develop peptide candidates for another rare endocrine disease of high unmet need." The IND-enabling studies for AMX0318, the long-acting GLP-1 receptor antagonist, remain underway with a 2027 IND filing targeted. In Wolfram syndrome, AMX0035's HELIOS open-label study showed week-96 stabilization across glycemic and visual measures, and the ALS program (AMX0114, a calpain-2 ASO) is enrolling cohort 3. The evolution from single-asset sponsor to platform company is visible in the collaboration with Gubra deepening.
Tape and Balance Sheet
The market has already voted. AMLX is up 136% in the trailing 90 days, and the full-history tape shows a name that lost ~80% through 2023–2025 and has now clawed back to within ~5% of its all-time high. The run into the readout is aggressive — and notably contrarian to a market tape dominated by AI data centers and high-bandwidth memory. This rare-disease biotech is riding its own wave, not the market's.
Financially, the company is pre-revenue, and the shape is a classic pre-launch burn:
R&D was $28M in the latest quarter, up 25% yoy — a re-acceleration after the post-2024 dip when the PSP program wound down.
The loss profile has widened to roughly -$44M of quarterly operating income as SG&A jumped for legal and commercial build-out, but the balance sheet remains the key support.
With $250.8M in cash and marketable securities at quarter end, management guides to a runway into 2028 — sufficient, on their plan, to fund the readout, a potential FDA approval, and commercialization.
All roads now lead to late August or early September. If the data hits, Amylyx has pre-built the entire commercial apparatus: NDA readiness, launch readiness, a new ICD-10 code, and an early-access channel already flowing. If it does not, the 136% run reverses just as violently. Few small-cap biotechs sit at a cleaner binary.